ArticleArchives of gynecology and obstetrics2025
Breast cancer in patients under 40 years: an 11-year retrospective cohort analysis.
Article in Archives of gynecology and obstetrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-world insights into bone marrow carcinomatosis in metastatic breast cancer: a retrospective analysis from two large university breast cancer centers.Journal of cancer research and clinical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe number of young breast cancer (BC) patients is increasing in both high- and low-income countries. It is known that this population is at risk for more aggressive tumor phenotypes, larger tumor size at diagnosis and poorer prognosis. It is the aim of this population-based analysis to identify trends of therapy, tumor biology and prognosis during a period of 11 years in young patients under the age of 40.
methodsIn this analysis, data of young BC patients (< 40 years) from two breast centers were collected and analysed. The focus was a summary of data regarding tumor phenotypes, treatment, and survival in young BC patients.
resultsOut of 11,954 patients with invasive BC who were eligible to the analysis, 781 (6.5%) were younger than 40 years at diagnosis and met the inclusion criteria. The predominant biological subtypes were Luminal B-like (HER2-) and Luminal-A-like, 62.3% were diagnosed with pN0. Noticeably low rates for endocrine therapy and higher rates for chemotherapy could be observed. 10-year overall survival was 87% for the whole cohort. Luminal-B-like (HER2-) and Triple negative tumors had worse outcomes as opposed to the other subtypes.
conclusionAs a conclusion, this 11-year analysis provides valuable insights into the clinical characteristics and treatment outcomes of young breast cancer patients under 40 years of age. The analysis highlights clear outcome differences according to the tumor subtype. These findings underscore the need for personalized treatment approaches and continued follow-up to optimize outcomes for young BC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.